Ultime notizie per Pharvaris (NASDAQ:PHVS) Azioni

Pharvaris

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .

Pharvaris NV

<p>UBS  analyst Steven Fisher   initiates coverage on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Buy rating and announces Price Target of $349.</p>


News

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Vulcan Materials with Buy Rating, Announces Price Target of $349

<p>WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.41 by 3.9 percent. This is a 15.27 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $22.851 million which missed the analyst consensus estimate of $23.203 million by 1.52 percent.  This is a 2.69 percent decrease over sales of $23.482 million the same period last year.</p>


Earnings

Earnings Misses

WhiteHorse Finance Q3 2024 Adj. EPS $0.39 Misses $0.41 Estimate, Sales $22.851M Miss $23.203M Estimate

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.</p>


Reiteration

ACAD

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

HOUS

Anywhere Real Estate Q3 2024 Adj. EPS $0.06 May Not Compare To $0.29 Estimate, Sales $1.535B Miss $1.624B Estimate

<p><strong>Fourth Quarter and 2024 Outlook</strong></p>
<p>The Company is reaffirming its fiscal year 2024 outlook of 4.5% to 5.5% revenue growth, based on year-to-date performance and current business trends. For the fourth quarter, the Company anticipates continued strong high single digit year-over-year growth in OEM &amp; National revenue, as well as modest growth in Dealer revenue.</p>
<p>Adjusted EBITDA margin outlook for fiscal 2024 remains 28.0% to 30.0%, reflecting disciplined cost management to continue delivering strong operating leverage for the remainder of the year.</p>


Guidance

CARS

Cars.com Reaffirms FY24 Revenue Outlook 4.5%-5.5% Growth

MTSI

MACOM Sees Q1 Adj. EPS $0.75-$0.81

<p>The earnings results for <strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) for Q3 were made public on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data in hand, it's essential to compare its metrics to those of similar companies, including PubMatic, TechTarget, and National CineMedia.</p>
<ul>
<li>The latest earnings announcement from PubMatic on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's estimate of $-0.02, resulting in a 950.0% increase.</li>
<li>The latest earnings announcement from TechTarget on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's estimate of $0.4, resulting in a 5.0% increase.</li>
<li>The latest earnings report from National CineMedia on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $-0.03, National CineMedia reported an EPS of $-0.04, marking a -33.33% decrease.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
<p>The provided analysis offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Delving into Peer Revenue Comparison: Estimated vs. Announced</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Clear Channel Outdoor Q3 Earnings

<p>MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) reported quarterly earnings of $0.73 per share which met the analyst consensus estimate.  The company reported quarterly sales of $200.710 million which beat the analyst consensus estimate of $200.406 million by 0.15 percent.  This is a 33.47 percent increase over sales of $150.375 million the same period last year.</p>


Earnings Beats

MACOM Technology Solns Q4 2024 Adj. EPS $0.73, Inline, Sales $200.710M Beat $200.406M Estimate

Turning Point Brands Raised Previous Full-year 2024 Adjusted EBITDA Guidance From $98M-$102M To $101M-$103M, Excluding CDS

THRY

Thryv Holdings See FY24 Adj. EBITDA $33.5M-$34.5M

Thryv Holdings Sees Q4 Adj. EBITDA $9.5M-$10.5M

<p>Seaport Global  analyst Aaron Kessler   downgrades Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from Buy to Neutral.</p>


Downgrades

DUOL

Seaport Global Downgrades Duolingo to Neutral

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) with a Buy and maintains $90 price target.</p>


DNLI

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

<p>Anywhere Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.62 billion by 5.46 percent.  This is a 3.09 percent decrease over sales of $1.58 billion the same period last year.</p>


Anywhere Real Estate Q3 Sales $1.53B Miss $1.62B Estimate

Stock Split

General

TRNR

Interactive Strength Announces 1-For-100 Reverse Split, Effective November 11

<p><strong>2024 Fourth Quarter Financial Outlook</strong></p>
<p>Management provided an outlook for the fourth quarter, the period ending December 31, 2024. Based on current estimates, management expects:</p>
<ul>
<li>$181 million to $191 million in revenue</li>
<li>$1.51 to $1.70 in diluted GAAP EPS</li>
<li>$1.72 to $1.91 in diluted non-GAAP EPS</li>
</ul>


NVMI

Nova Expects Q4 Revenue Of $181M-$191M Vs $171.84M Est, Adj EPS Of $1.72-$1.91 Vs $1.68 Est

<p>Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly losses of $(2.65) per share which missed the analyst consensus estimate of $(0.95) by 178.95 percent.  The company reported quarterly sales of $179.852 million which beat the analyst consensus estimate of $179.230 million by 0.35 percent.  This is a 2.16 percent decrease over sales of $183.822 million the same period last year.</p>


Thryv Holdings Q3 2024 GAAP EPS $(2.65) Misses $(0.95) Estimate, Sales $179.852M Beat $179.230M Estimate

<p>Barclays  analyst Lauren Lieberman   downgrades Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowers the price target from $8 to $7.</p>


COTY

Barclays Downgrades Coty to Underweight, Lowers Price Target to $7

<p>Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) affirms FY2024 sales outlook from $875.00 million-883.00 million to $875.00 million-883.00 million.</p>


PRTH

Priority Tech Holdings Affirms FY2024 Sales Guidance from $875.00M-883.00M to $875.00M-883.00M

<p>ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent.  The company reported quarterly sales of $18.464 million which beat the analyst consensus estimate of $18.462 million by 0.01 percent.  This is a 27.40 percent increase over sales of $14.493 million the same period last year.</p>


ADCT

ADC Therapeutics Q3 2024 Adj. EPS $(0.28) Beats $(0.40) Estimate, Sales $18.464M Beat $18.462M Estimate

Pharvaris (PHVS) has released an update. Pharvaris, a Dutch biopharmaceutical company, has executed the second amendment to its License Agreement w...

Pharvaris Refines License Terms with BRAIN Biotech

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris (PHVS – Research Report) today and set a price target of $34.00. The compa...

Morgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)

Pharvaris (PHVS) has released an update. Morgan Conn, Ph.D., the Chief Business Officer of Pharvaris N.V., has voluntarily resigned as of October 4...

Pharvaris CBO Resigns, Team Absorbs Duties

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pharvaris (PHVS – Research Report), Silence Therap...

Analysts Conflicted on These Healthcare Names: Pharvaris (PHVS), Silence Therapeutics (SLN) and Stevanato Group (STVN)

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $42.0...

Oppenheimer Sticks to Their Buy Rating for Pharvaris (PHVS)

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of ...

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

Pharvaris (PHVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Schwartz from L...

Comments

Pharvaris

Notizie

Ultime notizie per Pharvaris (NASDAQ:PHVS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO